Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials

Arcus Biosciences Inc. (NYSE:RCUS) is one of billionaire Steve Cohen’s 10 small-cap stock picks with huge upside potential. On October 6, Arcus Biosciences Inc. (NYSE:RCUS) announced encouraging data for its kidney cancer drug casdatifan. Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials The HIF-2a inhibitor demonstrated positive results across all efficacy measures in the Phase 1/1b study. In trials involving 121 patients across four immunotherapy cohorts, the candidate d ...